2017
DOI: 10.1001/jama.2017.7248
|View full text |Cite
|
Sign up to set email alerts
|

The Diagnosis and Treatment of Prostate Cancer

Abstract: Advances in the diagnosis and treatment of prostate cancer have improved the ability to stratify patients by risk and allowed clinicians to recommend therapy based on cancer prognosis and patient preference. Initial treatment with chemotherapy can improve survival compared with androgen deprivation therapy. Abiraterone, enzalutamide, and other agents can improve outcomes in men with metastatic prostate cancer resistant to traditional hormonal therapy.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
822
1
17

Year Published

2018
2018
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 1,144 publications
(918 citation statements)
references
References 95 publications
2
822
1
17
Order By: Relevance
“…At present, radiation, surgery or pharmacological androgen deprivation therapy is the most common treatments against PCa, especially for hormone-dependent PCa (HDPC). Although many PCa patients have HDPC, unfortunately, the vast majority of them finally become hormonal refractory PCa (HRPC) or castration-resistant PCa (CRPC) patients after 18 to 24 months [1, 2]. CRPC has become one of the difficult problems for urologists and oncologists due to its high metastatic potential, resistance to chemotherapeutic agents and easy relapse.…”
Section: Introductionmentioning
confidence: 99%
“…At present, radiation, surgery or pharmacological androgen deprivation therapy is the most common treatments against PCa, especially for hormone-dependent PCa (HDPC). Although many PCa patients have HDPC, unfortunately, the vast majority of them finally become hormonal refractory PCa (HRPC) or castration-resistant PCa (CRPC) patients after 18 to 24 months [1, 2]. CRPC has become one of the difficult problems for urologists and oncologists due to its high metastatic potential, resistance to chemotherapeutic agents and easy relapse.…”
Section: Introductionmentioning
confidence: 99%
“…Currently, early detected organ confined CaP is managed by active surveillance, surgery or radiation therapy (2). A significant subset of CaP patients (20% to 40%) experience biochemical recurrence after definitive treatment prompting hormone ablation and chemo therapy (3).…”
Section: Introductionmentioning
confidence: 99%
“…For men with less aggressive disease, particularly those with PSA less than 10 ng/ml and Gleason score less than 6, active surveillance is the preferred approach. [11] Radical prostatectomy and radiation therapy still offer the best hope for cure in patients with localized disease. [11] Despite the recent change in therapeutic landscape, metastatic disease remains incurable and often fatal.…”
Section: Published By Sciedu Pressmentioning
confidence: 99%
“…[11] Radical prostatectomy and radiation therapy still offer the best hope for cure in patients with localized disease. [11] Despite the recent change in therapeutic landscape, metastatic disease remains incurable and often fatal. ADT with a GnRH agonist or antagonist remains the mainstay of systemic therapy for locally advanced and metastatic prostate cancer.…”
Section: Published By Sciedu Pressmentioning
confidence: 99%